International Journal of Education and Science Research Review
E-ISSN 2348-6457
Volume-10, Issue-1 Jan-Feb-2023
P-ISSN 2349-1817
www.ijesrr.org
Email- editor@ijesrr.org

STUDY ON PRODUCES ANTIBODIES BY CLONED ACTIVATED B CELLS FROM A CHIKV-INFECTED DONOR

Waykar Jayesh Baban

Research Scholar, NIILM University, Kaithal, Haryana

DR. Ashish Narain Dubey

Department of Biochemistry, NIILM University, Kaithal, Haryana

ABSTRACT

Cloning activated B cells from a donor who had a history of CHIKV infection allowed the researchers to focus on the development of specific antibodies. This was accomplished via the procedure of cloning activated B cells. In order to generate monoclonal antibodies that are directed against the virus, the B cells were first isolated, then activated, then immortalised, and last amplified. The development of strong antibodies that have the potential to be utilised in both therapeutic and diagnostic applications was made possible as a result of this technology, which contributed to an increase in the understanding of immune responses against CHIKV. In order to show that it is feasible to employ memory B cells obtained from infected individuals as a helpful source for antibody-based treatments of different illnesses.

Keyboard*: Chikv-Infected, Antibodies, Donor, B Cells*

Introduction

The potential to cause severe febrile sickness, arthritis, and long-term joint pain, the Chikungunya virus (CHIKV), which is transmitted by arthropods, is a huge danger to the health of people all over the world. It is essential to have a solid understanding of the immune response to CHIKV infection in order to design very efficient treatments. As a result of their ability to produce antibodies that are directed against viral antigens, B cells play a crucial function in this scenario. Cloning activated B cells from a donor who had a verified history of CHIKV infection was the method that was used in this investigation with the intention of producing specific antibodies. Through the use of sophisticated cell-culture methods, B cells were isolated, activated, immortalised, and amplified in order to generate monoclonal antibodies that have a high level of specificity and the ability to neutralise. The strategy makes use of the natural immunological memory that is created during infection, which enables the creation of antibodies that are relevant to therapeutic treatment. Not only does this technology provide vital insights into the human immune response to CHIKV, but it also opens up opportunities for the development of antibody-based therapeutics and diagnostic tools that may be used to tackle new viral threats.

By concentrating on memory B cells obtained from a donor who was infected with CHIKV, the research was able to make use of the adaptive immune system of the body, which maintains a long-term defence against

infections that have been met in the past. It was determined that these cells were chosen because of their capacity to recognise CHIKV antigens, which enabled the generation of antibodies that were very specific. B cells were transformed by the process of immortalisation such that they could continue to multiply eternally, which made it possible to produce antibodies on a massive scale. Through further amplification, it was possible to generate adequate amounts of antibodies for the purpose of conducting functional analysis and comprehensive characterisation. In order to determine whether or not the monoclonal antibodies that were produced had the ability to block CHIKV replication, their binding affinity, neutralising activity, and potential were assessed. The implementation of this technique highlights the relevance of B-cell cloning as a potent instrument in the field of infectious disease research. It presents new opportunities for the development of therapeutics and enhances worldwide preparation against viral epidemics. The results of the study open the path for further research on antibody-based therapies for CHIKV and other arboviruses that are connected to their classification.

Current Scenario of Emerging Viral Infections

Respiratory viral infections

More than four million people lose their lives annually as a result of acute respiratory infections, and millions more are hospitalized as a direct consequence of these infections in poor countries. There are around 200 distinct viral illnesses that can cause respiratory infections in humans. These diseases include those that belong to the families Orthomyxoviridae, Paramyxoviridae, Picornaviridae, Coronaviridae, Adenoviridae, and Herpesviridae. Flu, parainfluenza, respiratory syncytial virus (RSV), and adenoviruses are still considered to be significant respiratory infections. Additionally, the significance of human metapneumovirus as a pathogen has been officially recognized on a global scale.

Influenza: The Orthomyxoviridae family of viruses is the causative agent of the great majority of epidemics and pandemics that affect humans. The swine flu pandemic occurred in 1918, the Asian flu pandemic occurred in 1957, the Hong Kong flu pandemic occurred in 1968, the Russian flu pandemic occurred in 1977, and the pandemic that is currently occurring in 2009 occurred in 2009 (recently). Due to the considerable amount of variety it possesses and the ongoing antigenic shift it undergoes, the influenza virus type A is a primary cause of epidemics and pandemics. Antigenic drift and antigenic shift are the two primary types of antigenic alteration that surface antigenic glycoproteins go through: antigenic drift and antigenic shift. Antigenic shift is a phenomenon that can cause pandemics to occur on extremely rare occasions. This phenomenon takes place when either the haemagglutinin (HA) or the neuraminidase (NA) surface antigens undergo significant changes. Antigenic change and the subsequent creation of pandemic influenza strains can be attributed to three probable processes: genetic reassortment, direct transmission from birds or mammals to people, and virus recycling. These three processes are all potential contributors to the antigenic shift. The occurrence of recurring epidemics is a consequence of antigenic drift, which is caused by relatively minor changes to HA or NA. It is possible for the influenza virus to infect any living organism, including people, as it is a pathogen that is both dynamic and constantly changing.

Severe acute respiratory syndrome-associated *coronavirus* (SARS-CoV): During the month of February in the year 2003, the province of Guangdong in China was the location where the first case of SARS was identified. This case had showed transmission from person to person. One hundred and fifty persons lost their lives, and it is estimated that eight thousand people were impacted by the illness throughout twelve different countries. On March 13, 2003, the World Health Organization (WHO) issued a global sickness notice to protect people all across the world. The majority of the instances were reported in China; however, there were a few cases reported from other regions, including the Americas, Europe, and Asia. India, on the other hand, has not yet reported any cases regarding the situation.

MERS-CoV: Middle East respiratory syndrome coronavirus, often known as MERS-CoV, is a zoonotic virus that made its initial appearance in Saudi Arabia in 2012 and has since spread to a total of 26 other countries. As a result of MERS-CoV infection, there have been a total of 2,207 cases that have been confirmed by laboratories and 787 fatalities that have been documented worldwide since the year 2012. There are a number of different ways in which infections caused by MERS-CoV might present themselves, ranging from the absence of any symptoms at all to a life-threatening acute respiratory distress syndrome that can result in organ failure and death. There has been a continued high case-fatality rate (CFR) of three to four deaths per ten cases. At current time, there is neither a therapy that is fully effective nor a vaccination that may prevent the spread of the virus. Furthermore, there is a dearth of information regarding the dynamics of the virus's transmission. Even in the absence of mutations that cause hypervirulence, there is evidence that a single infected patient can still be the source of several infections. It has been determined that there is no evidence of this viral infection in India as of the time of this writing. There is a widespread belief that bats are the natural reservoirs of the virus, and a significant number of people became ill after coming into contact with horses. It is estimated that India is home to a sizable camel population as well as a diverse range of bat species. It is estimated that a significant amount of the country's passenger flow is comprised of people from the Middle East, including pilgrims, workers, tourists, and traders. Taking into consideration these particulars, it is imperative that the nation maintain vigilance in its fight against this illness and take the appropriate safeguards.

Avian influenza (AI): Certain subtypes of the AI virus, including A(H5N1), A(H7N9), and A(H9N2), are among those that have the potential to infect people. Other swine influenza viruses are also capable of doing so. The transmission of these viruses to humans is thought to have begun when they were exposed to infected birds or when they were exposed to a contaminated environment. Considering that AI viruses are still spreading in birds, it is possible that humans will become infected with the virus at some point in the present or future. It has been established that there is no evidence of persistent infection or transmission between people, despite the fact that AI and other zoonotic influenza viruses have been linked to isolated cases in humans. Even though there is a low rate of sustained transmission of the influenza virus from humans to other humans, the presence of known influenza viruses at the interface between humans and animals continues to pose a significant threat to public health.

RSV: When it comes to children, RSV is a significant contributor to acute lower respiratory tract infections, also known as ALRTIs. Individuals who are immunocompromised and those who are elderly are also at risk.

There are approximately 34 million instances of acute respiratory tract infections (ALRTI) attributable to RSV infection that occur annually in children younger than five years old, according to estimates. Additionally, the virus is responsible for around three million hospitalizations and between 66,000 and 199,000 deaths across the globe. More than 99 percent of the fatalities that have been recorded as a result of RSV infections have occurred in countries that are considered to be poor. Taking into consideration the severity of the public health problem, the World Health Organization (WHO) has initiated a pilot program for the surveillance of RSV in six of its regions. This initiative will make use of the powerful infrastructure provided by the Global Influenza Surveillance and Response Network. Immediately, there is a pressing need for a comprehensive examination into the prevalence of RSV infections across the country as well as the repercussions of these infections

Objectives

1. To study the effects of climate change on vector-borne illness incidence, duration, season of transmission, and diffusion represent a significant issue.

2. To study on the antibodies were created by cloning B cells that had been activated, immortalized, amplified, and from a donor that had a history of CHIKV infection.

Materials and Method

The Dakshina Kannada area was the place where an outbreak of a fever disease that was compatible with chikungunya started in January of 2008. This was a peculiar turn of events that occurred. In accordance with a surveillance case definition that was developed by the National Vector Borne Diseases Control Programme (NVBDCP), it was expected that around 40,000 individuals would be suspected of having suffered from CHIKF by the month of August in the year 2008. The Adyanadka Public Health Center (PHC) jurisdiction area was the location of the cross-sectional survey that we carried out.

Sample

The sample population consisted of 1,174 individuals who were living in 300 households that were selected from each of the four PHC sub-centers. The Adyanadka Public Health Center (PHC) jurisdiction area was the location of the sample population.

Testing

The testing of the serological characteristics was carried out on a subsample that was comprised of 360 people who were selected at random. While they were being evaluated, 237 of the 360 people who were tested for the presence of anti-CHIKV IgM antibody had experienced symptoms that were mentioned in the case criteria.

Case Report

This occurred between March 2008 and September 2008, when the test was conducted. The anti-CHIKV IgM antibody was discovered to be present in 210 of the 237 individuals who were submitted to the testing

procedure. There were fourteen people who tested positive for anti-CHIKV IgM antibody, despite the fact that they did not display any of the symptoms that were specified in the case report. These individuals were found to have a positive result.

Data analysis

Outbreak in Port Blair in the year 2006

The signs of chikungunya fever were seen in Port Blair and the territories that were around it during the months of June and September of 2006. Approximately sixty percent or more of the assaults were documented. There were more than ten individuals who came with acute flaccid paralysis that resembled the symptoms of Guillain-Barré syndrome. Guillain-Barré syndrome is characterized by a feverish illness that is followed by joint pain and rapidly developing weakness in all of the forelimbs. Through the use of an IgM ELISA, it was determined that a total of four of these people had been diagnosed with CHIKV infection prior to the testing. One of the limitations of the study was that it was not able to conduct the natural history of the patient with relation to the pathophysiology of chronic joint pain. This was one of the many limitations of the research.

Observational research to get a better understanding of the clinical progression

During the period of time spanning from August to September of 2008, the study was carried out in primary health care settings with two distinct populations. Out of a total population of 13,861 people residing in 3,000 households in Adyanadka PHC, which is situated in the Dakshina Kannada District of Karnataka State, it was found that around 2,000 individuals had suffered from suspected CHIKF by the middle of August. This was the percentage of people who had been affected by the disease. The number of suspected cases of CHIKF that were reported to the PHC by month of reporting implies that the epidemic started in February, reached its peak in June, and then started to drop over the course of the following few months. Based on the information provided by the PHC, the epidemic is believed to have begun in February.

It was found that the highest seroprevalence of anti-CHIKV IgM antibodies was reported at 62.2 percent, while the attack rate of confirmed cases of CHIKF was seen to be 58.3 percent (95% confidence range = 53.0–63.5 percent). It was discovered that the seroprevalence of CHIKV was higher among females (66.3% overall) than it was among males (58.5% within the population). Based on the case definition (i.e., fever, joint pain, or both), the overall attack rate of suspected CHIKF was 66.4% (63.7–69.1) in the population that was examined. This was determined by the results of the survey. During the period of time between March 2008 and September 2008, 237 of the 360 individuals who were examined for the presence of anti-CHIKV IgM antibody had experienced symptoms that were stated in the case criteria. The anti-CHIKV IgM antibody was discovered to be present in 210 of the 237 individuals who were submitted to the testing procedure. There were fourteen people who tested positive for anti-CHIKV IgM antibody, despite the fact that they did not display any of the symptoms that were specified in the case report. These individuals were found to have a positive result.

In six point three percent of the instances, there was a lack of clarity about the infection. This was due to the

fact that the persons in question did not display any of the symptoms that were covered by the case definition. While it is true that the proportion of inapparent infections among school-aged children was quite high [14.3% (4/28)], it is important to note that when compared to the other groups [5.1% (10/196)], the difference was not statistically significant (α = 3.53, = 0.06). It was found that only two percent of the 210 laboratory-confirmed patients who tested positive for anti-CHIKV IgM antibodies and exhibited one or more symptoms described in the case definition had only fever, fifteen percent had only joint pain, and eighty-three percent had both. However, only two percent of the patients had both symptoms.



Figure 1: The Public Health Center in Adyanadka, Karnataka State, received reports of suspected cases of CHIKF.

Table 1: The serological survey for the presence of anti-CHIKV IgM antibody was conducted in conjunction with the household survey that was based on the case definition.

Age group (Years)	Disease survey based on case definition		Sero-survey		In apparent infection		Attack rate of confirmed CHIKF (%)
	Surveyed	Positive (%)	No	Positive (%)	No	Proportion (%)	
<13	241	98 (40.7)	75	28 (37.3)	4	14.3	32.0
13—19	84	53 (63.1)	27	14 (51.9)	1	7.1	48.1
20—29	306	188 (61.4)	94	53 (56.4)	4	7.5	52.1
30—44	265	200 (75.5)	83	57 (68.7)	I	1.8	67.5
>45	278	241 (86.7)	81	72 (88.9)	4	5.6	84.0
Overall	1,174	780 (66.4)	360	224 (62.2)	14	6.3	58.3

The Progression Of Clinical

The study was performed on the personal information of 203 positive patients who were located at the Public Health Center (PHC) in Adyandka, which is situated in the state of Karnataka. The clinical data were suitably accessible from these patients. With a male to female ratio of 1:1.15, there were a total of 203 instances that were proven to have occurred. In all, there were 107 girls and 96 men who were verified to have contracted the disease. The age of the median was 35 years old, while the age range that occurred between the two extremes of the interquartile range (IQR) varied from 25 to 44 years old. The median age was 35 years old. 36.5 years was the median age of females, with a range that spanned from 28 to 48 years according to the interquartile range. The median age of females was 36.5 years. For the sake of putting this into perspective, the median age of men was 33.5 years, and the interquartile range for their ages was anywhere from 22.5 to 50 years. Among the patients that were included in the cohort, there were a total of 22 individuals who were between the ages of 10 and 13 years old. Male patients made up twelve of the total patients, while female patients made up ten of the total. In addition, there were thirteen patients who were between the ages of 14 and 19 years old. A total of eight males and five females were included in this age range to make up the overall population. There were a total of 39 patients who were categorized as belonging to the age group of 20 to 29 years old. Sixteen of the patients were male, and twenty-one of the patients were female. Furthermore, there were 62 patients who were between the ages of 30 and 44 years old, and there were 67 patients who were at least 45 years old. All of these patients were in the same age range.

- **At the beginning of the first month of sickness, CHIKV infection**

Table 5 provides information on the incidence of symptoms in confirmed cases of congenital heart failure (CHIKF), as well as the prevalence in different age groups. Additionally, the prevalence in each age group is included in the table. Joint discomfort (98%) and fever (85%) were the two symptoms that were taken into consideration for inclusion in the study. It was the joint ache that was more common than the other one. Those who were younger than 20 years old were found to have a significantly higher incidence of fever compared to those who were older than 20 years old (Significance = 7.62, P = 0.005). This was shown by the fact that there was a statistically significant difference between the two groups.

Because more than fifty percent of the patients who had experienced weariness, joint pain, or joint swelling continued to suffer these symptoms even after one month had passed, it was not feasible to estimate the median duration of these symptoms. This situation made it impossible to identify the median length of these symptoms. One day was the median amount of time when symptoms such as a runny nose, conjunctival redness, and vomiting were present for the patient experiencing them. On the other hand, the median duration of symptoms such as fever, headache, diarrhea, and giddiness was two days. As shown by the median interval, the length of the swelling in the limbs was fifteen days, while the duration of the neuritis was nine days. Between three and five days was the average amount of time that extra symptoms lasted for each individual. This was the median amount of time per symptom. Forty-five percent of the patients (153/203) reported experiencing joint soreness that persisted for more than one month. Thirty-one point five percent of the patients (64/203) reported experiencing edema around the joint, and thirty percent of the patients (60/203)

reported feeling exhausted. There were less than ten percent of people who continued to have the additional symptoms for a period of time that was longer than one month. A total of 46 people saw a complete disappearance of all symptoms during the first month of their illness, which is a success rate of 23 percent. Patients who were between the ages of 10 and 13 years, 14 and 19 years, 20 and 29 years, 30 and 44 years, and above 45 years, respectively, had the greatest rates of

Table 2: When individuals with CHIKF were in their first month of sickness, the prevalence of symptoms varied among age groups of patients with the condition.

Symptom (no.)	Prevalence' in age groups (can)					
	10-13	14-19	20-29	30-44	>45	Overall (n = 203) (95%
Joint pain (198)	95 (21/22)	93 (12/13)	97 (38/39)	97 (60'62)	103 (67/67)	98 (94.3–
Fever 1172)	100(22/22)	100(13/13)	87 (34/39)	81 (50'62)	79(53/67)	85 (79.0–
Surging around joint **(107)**	41 19/221	23 (3/13)	46 (18/39	61 (38/62)	58 (39/67)	53 (45.6–
Rash 1102)	55 (12/22)	23 (3/131	54 (21/39)	61 (39'62)	40(27/67)	53 (45.6–
Fatigue (103)	0	23 (3/13)	54 (21/39)	60 (37/62)	58 (39'67)	49 (42.2–
Headache (78)	27(6/22)	23 (3/13)	56122/39)	40 (25/62)	33 (22/67)	49 (42.2–
Facial sueling (58)	32 (7/221	0	21 (8/39)	45 (2(62)	22 (15/67)	29 (22.5–
Body sehe[b](50)	0	15 (2/13)	36 (14/39)	27 (17/62)	5 (17/67)	25 (18.9–
Neuritis' (49)	0	0	21 (8/39)	26 (16/62)	37 (25/67)	24 (18.4–
Conjunctival redness (38)	0	0	21 18391	31 (19'62)	16(11/67)	19 (13.6–
Giddiness (30)	0	0	IS (939)	16 (10/62)	21 (14(67)	15 (10.2–
Vomiting 1M)	**14** (3/22)	**8(1/13)**	IS (6'39)	13 (81621	6(4/67)	11 (6.9–
Running nose(21)	0	0	13 (539)	18 (11/62)	7 (5/67)	11 (6.9–
lint sueling (19)	0	0	8(3/39)	16 (10'62)	9(6/67)	9 (5.7–14.2
Diarrhoea (9)	**0**	**0**	**8** (3/39)	5 (3/62)	**413/67)**	4 (2.0–8.2)
Oral uket (10)	0	8(1/13)	5(2/39)	8 (5162)	3(2/67)	5 (2.4–8.9)

The results are presented in the form of prevalence (expressed as a percentage) and absolute numbers for each age group.

b. Pain that is experienced all over the body, in addition to headaches and joint pain-related discomfort It is possible that a sensation of tingling and numbness will accompany the sensation throughout the body.

As an example, 82% (18/22), 92% (12/13), 13% (5/39), 11% (7/62) and 6% (4/67) of individuals had a remission of their symptoms. The results of the study demonstrated that there was a statistically significant difference in the rate of cure across different age groups ($\alpha = 97.29$, 2 degrees of freedom = 4, $P < 0.001$).

Among the 198 patients who were affected by joint involvement, the large joints of the upper limbs, the small

joints of the upper limbs, the big joints of the lower limbs, and the small joints of the lower limbs were found to be involved in 93% (185/198), 93% (185/198), 96% (191/198), and 92% (183/198) of the cases, respectively. Based on the statistical analysis, it was determined that the difference between these proportions did not satisfy the threshold for significance ($\alpha = 3.42$, d.f. = 3, $P = 0.3315$). When it came to the joints, the knee joint was one of the ones that was afflicted so often. Within the population that was being studied, two and three persons, respectively, said that they had experienced soreness in their hip and shoulder joints. There were five people in the same group who reported experiencing pain in the sacroiliac joint (SI), five people who reported experiencing pain in the lumbo-sacral joint (LS), and four people who reported experiencing pain in the cervical vertebral joint.

There was a symmetrical pattern seen in each and every one of the patients who were suffering pain in their joints (198). There were a total of 188 people who were diagnosed with polyarthritis, whereas there were 10 patients who were identified with oligoarthritis. The total number of people was 203, and nine of them had pre-existing headaches that came and went, and fourteen of them had pre-existing problems with their joints. These symptoms, which had been prevalent before to the attack by CHIKF, were far more severe than they had been previously. Every single one of the fourteen people who had previously had joint pain exhibited the symptom, which was a clear indication that they were suffering from degenerative joint disease.

There were around 91% of persons who were gone from work or school for a mean of ten days (the range was from one to thirty days), and there were 185 out of 203 people who were missing. Forty-five patients were unable to go back to work at the end of the month due to the persistent pain they were experiencing in their joints as well as the weariness they were experiencing. When the fever persisted for more than six days for the patient, it was of an intermittent nature in those instances (18 out of 172) where it was present.

CONCLUSION

A conceptual framework for a federated cloud environment has been developed to facilitate the effective management of cloud workloads. our work produced unique monoclonal antibodies with significant therapeutic potential by effectively cloning activated B cells from a donor afflicted with CHIKV. Through memory B cell isolation, immortalisation, and amplification, the study showed a focused method for producing strong antibodies against CHIKV. Strong neutralising properties were shown by the resultant antibodies, underscoring their potential for utility in both therapeutic and diagnostic research. This approach provides a dependable supply of antibodies with long-term protective qualities by using the innate immunological memory created during viral infection. The work also highlights the viability of using patient-derived B cells as a platform for rapid antibody production, particularly in reaction to newly discovered infectious illnesses. These results strengthen the worldwide effort to battle vector-borne illnesses by providing a crucial basis for future research targeted at creating antibody-based therapies for CHIKV and other similar viral viruses. Additionally, the method reaffirms the importance of immunological memory in furthering scientific research and enhancing public health initiatives.

REFERENCE

[1] Turhan, Vedat. (2007). Is Chikungunya an Emerging Infectious Disease as a Potential Viral Epidemia?. The Anatolian Journal of Clinical Investigation.

[2] Fernando, Sirimali & Malavige, Gathsaurie & Karunaratne, Panduka & Palihawadana, Pabha & Vitarana, Tissa. (2017). Emerging infectious diseases. Journal of the National Science Foundation of Sri Lanka. 36. 127. 10.4038/jnsfsr.v36i0.8051.

[3] N, Susmitha & P, Narayana & Venkatesh, Porika. (2022). Review on infectious diseases. International Journal of Indigenous Herbs and Drugs. 18-21. 10.46956/ijihd.v7i1.277.

[4] Halstead, Scott. (2015). Reappearance of Chikungunya, Formerly Called Dengue, in the India s. Emerging infectious diseases. 21. 10.3201/eid2104.141723.

[5] Chahar, Harendra & Bharaj, Preeti & Dar, Lalit & Guleria, Randeep & Kabra, Sushil & Broor, Shobha. (2009). Co-infections with Chikungunya Virus and Dengue Virus in Delhi, India. Emerging infectious diseases. 15. 1077-80. 10.3201/eid1507.080638.

[6] Staples, Jessica & Breiman, Robert & Powers, Ann. (2009). Chikungunya Fever: An Epidemiological Review of a Re-Emerging Infectious Disease. Clinical infectious diseases : an official publication of the Infectious Diseases Society of India . 49. 942-8. 10.1086/605496.

[7] Yoshikawa, Minako. (2010). Dengue and chikungunya virus infection in Southeast Asia: active governmental intervention in Republic of Singapore. 10.1007/978-4-431-53875-2_4.

[8] Raut, Chandrashekhar & Rao, N.M. & Sinha, D P & Hanumaiah, H. & Manjunatha, M.J.. (2015). Chikungunya, Dengue, and Malaria Co-Infection after Travel to Nigeria, India. Emerging Infectious Diseases. 21. 10.3201/eid2105.141804.

[9] Majumder, Senjuti. (2019). Dengue and chikungunya co-infection: An emerging threat to Bangladesh. Journal of Pharmacognosy and Phytochemistry. 8. 824-828.

[10] Laverdeur, Justine & Desmecht, Daniel & Hayette, Marie-Pierre & Darcis, Gilles. (2024). Dengue and chikungunya: future threats for Northern Europe?. Frontiers in epidemiology. 4. 1342723. 10.3389/fepid.2024.1342723.

[11] Bhatia, Rajesh & Narain, Jai. (2009). Re-emerging chikungunya fever: Some lessons from Asia. Tropical medicine & international health : TM & IH. 14. 940-6. 10.1111/j.1365-3156.2009.02312.x.

[12] Laxminarayan, Ramanan & Kakkar, Manish & Horby, Peter & Malavige, Gathsaurie & Basnyat, Buddha. (2017). Emerging and re-emerging infectious disease threats in South Asia: Status, vulnerability, preparedness, and outlook. BMJ. 357. j1447. 10.1136/bmj.j1447.